76 results about "Fat mouse" patented technology

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention relates to application of 9-cis-retinoic acid in preparation of products for treating, preventing or improving obesity, and belongs to the technical field of biological medicine. Experimental evaluation of obese mice induced by high-fat diet proves that the 9-cis-retinoic acid can reduce blood fat and improve the glycometabolism function, and lipid accumulation of the liver is improved mainly by increasing expression of main regulatory protein PPAR-alpha oxidized by liver beta, so that the 9-cis-retinoic acid can be used for preparing medicines for treating obesity. The traditional Chinese medicine composition can be used for treating, preventing or improving metabolic symptoms caused by high fat diet, and a new strategy is provided for treating obesity and related metabolic syndromes. Besides, 9-cis-retinoic acid is a natural active metabolite of vitamin A, does not show obvious toxic reaction in animal experiments, and has better biocompatibility.

The invention discloses a microneedle raw material composition, a microneedle formed by the microneedle raw material composition and an ultrasonic regulation and control gene editing system, the microneedle raw material composition comprises CRISPRa-UCP1 plasmid (aUCP1) loaded in a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) and used for up-regulating UCP1, and the MOF is MOF modified by mPEG-PEI. And the browning of white fat cells is promoted through the controllable release of the CRISPRa-UCP1 system. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound. The research provides a new standard treatment mode for gene therapy of obesity and other metabolic diseases.

The invention discloses a microneedle raw material composition as well as a microneedle and a sonodynamic system formed by the microneedle raw material composition. The microneedle raw material composition comprises a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) modified by mPEG-PEI. The sonodynamic system provided by the invention can kill redundant white fat cells. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound.

Mouse models of obesity associated with human MC4R missense mutations are provided. Human mutations introduced with CRISPR / Cas9 into the mouse MC4R gene lead to an severely obese mouse phenotype in mice with a heterozygous genotype.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to an application of a ligusticum wallichii alcohol extract and an active monomer thereof in preparation of a product for relieving or treating food-borne obesity. Experimental research finds that when the ligusticum wallichii alcohol extract is singly used, the mRNA expression level of POMC in hypothalamus of a high-fat diet induced food-borne obesity mouse can be reduced, the alpha-MSH level in the hypothalamus can be improved, appetite can be effectively inhibited, body weight can be reduced, meanwhile, the number of lipid droplets in the liver can be reduced, and the ligusticum wallichii alcohol extract has the effects of relieving and treating food-borne obesity, preventing and treating hyperlipidemia and the like. And the application potential of liver tissues is improved, and a new direction and theoretical support are provided for treating food-borne obesity and expanding the medication range of ligusticum wallichii.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite active polypeptide composition with a weight losing effect and a preparation method thereof. The composite active polypeptide composition comprises NT analogue polypeptide ELP3, mulberry leaf polypeptide, balsam pear polypeptide, sea cucumber polypeptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is as shown in SEQ ID NO. 1. According to the present invention, the artificial peptide fragment AYYKSQWLVNGEGTP is added to the end of the wild type NT, such that the gastric acid secretion can be inhibited, and the activity of the alpha-amylase can be significantly inhibited; the NT analogue polypeptide ELP3 and various polypeptide components are matched to achieve a synergistic effect, so that the blood fat metabolism condition of obese mice can be effectively improved, and the fat weight of the mice is reduced; meanwhile, the food intake of the mice can be remarkably inhibited, so that the purpose of reducing the weight of the mice is achieved, and a good weight-losing effect is achieved.

The present invention relates to a preparation method of an exocrine protein Pc and its application in regulating intestinal flora. The fungal-derived Pc protein directly interacts with a protein in the intestinal microorganisms that has exocrine properties and contains a β-N-acetylglucosaminidase (GL) domain and inhibits its enzymatic activity, thereby regulating the proliferation of beneficial microorganisms by alleviating cellular iron and ROS pressure. The Pc protein can regulate the expression of bifunctional autolysins, and can enrich beneficial Staphylococcus bacteria with bifunctional autolysins in the insect intestine, or can enrich beneficial Lachnospiraceae bacteria with bifunctional autolysins in the intestines of healthy mammalian mice, or can enrich Blautia bacteria in the intestines of obese mice induced by a high-fat diet, or can enrich Akkermansia bacteria in the intestines of mice with DSS-induced colitis. The Pc protein can significantly reduce the formation of biofilms of Staphylococcus aureus (S. aureus) with bifunctional autolysins. Pc protein can be used as a new potential prebiotic to regulate the proliferation of beneficial intestinal microorganisms with bifunctional autolysins, and has potential application value in the preparation of food, medicine and disease treatment.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present application relates to the technical field of central obesity related research and treatment, by constructing a central obesity mouse model, it is found that the up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance. A BDNF fusion polypeptide composed of TAT cell-penetrating peptide, flexible linker and BDNF mature peptide is designed and prepared, the fusion polypeptide has strong cell viability promoting effect at the cellular level, can effectively activate the BDNF signaling pathway and has better stability than natural BDNF protein; an anti-TrkB monoclonal antibody with high affinity and high titer is also prepared. In vivo experiments show that the BDNF fusion polypeptide and its combination with the anti-TrkB monoclonal antibody can effectively inhibit the weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate the TrkB signaling pathway, and the combination has better synergistic therapeutic effect, which provides a new direction and experimental basis for the treatment of central obesity.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of Caribik Meyer yeast and application thereof. The strain is isolated from natural plant enzymes. In an in-vitro test, the strain has relatively high TG (Triglyceride) degradation capacity and T-CHO (T-CHO) degradation capacity; in an in-vivo test, the enzyme prepared by fermenting a seed solution of the strain can effectively reduce the weight, fat coefficient and blood fat level of obese mice and relieve pathological changes of fatty liver, has no obvious toxic or side effect, and can be used as a candidate for replacing weight-reducing medicines, so that the enzyme has good practical application value.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to application of a codonopsis pilosula aqueous extract in preparation of a product for relieving or treating food-borne obesity. It is found for the first time through experimental research that the codonopsis pilosula aqueous extract can effectively improve the leptin level in hypothalamus of a food-borne obese mouse, inhibit expression of neurons NPY / Agrp for promoting ingestion and relieve central leptin resistance, so that appetite is reduced, food intake is reduced, then body weight is reduced, lipid deposition in the liver is reduced, and the weight of the mouse is reduced. Therefore, the composition can be used for preparing products for relieving or treating the food-borne obesity, such as functional foods beneficial to controlling fat in a body or medicines for treating the food-borne obesity or relieving symptoms of the food-borne obesity. The composition can be used for preparing the products for relieving or treating the food-borne obesity, such as the functional foods beneficial to controlling fat in the body or the medicines for treating the food-borne obesity or relieving symptoms of the food-borne obesity.

The present application belongs to the field of biomedical technology, and specifically relates to a breast milk-derived polypeptide and its application in preventing and treating childhood obesity. The breast milk-derived polypeptide provided in the present application has an amino acid sequence as shown in SEQ ID NO.1, and the breast milk-derived polypeptide has significant effects in enhancing thermogenesis of brown adipose tissue in lactating mice, reducing the body weight of obese mice mediated by a high-fat diet, improving glucose metabolism, enhancing mitochondrial quality, and reducing mitochondrial autophagy. The breast milk-derived polypeptide and its pharmaceutical composition have good application prospects in the preparation of drugs for preventing and treating childhood obesity.

The invention relates to the technical field of central obesity related research and treatment, and discovers that up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance by constructing a central obesity mouse model. A BDNF fusion polypeptide composed of a TAT cell-penetrating peptide, a flexible connecting peptide and a BDNF mature peptide is designed and prepared, and the fusion polypeptide has a strong cell activity promoting effect at a cellular level, can effectively activate a BDNF signal channel and has stability superior to that of natural BDNF protein; the invention also discloses an anti-TrkB monoclonal antibody with high affinity and high titer. In-vivo experiments show that the BDNF fusion polypeptide and the composition of the BDNF fusion polypeptide and the anti-TrkB monoclonal antibody can effectively inhibit weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate a TrkB signal channel, the synergistic treatment effect of the composition is better, and a new direction and an experimental basis are provided for treatment of central obesity.

The invention provides application of propyl gallate in preparation of anti-obesity drugs or functional food for weight management, and belongs to the field of biological medicine technology and food. The invention discloses that the propyl gallate has the health benefit of positively regulating basic metabolism for the first time, and the propyl gallate can obviously reduce the weight of obese mice induced by high fat diet, reduce body fat, effectively relieve obesity and improve metabolic conditions such as glucose tolerance and insulin resistance; and brown fat can be activated to produce heat, respiratory metabolism and energy consumption are enhanced, and a new way is opened up for preventing and / or treating obesity. Propyl gallate is an edible substance, is high in safety and oxidation resistance, and is widely used as a food antioxidant, so that propyl gallate can be used for preparing anti-obesity drugs or functional foods for weight management, and has a good application prospect.

The invention belongs to the field of biological medicine, and particularly relates to a construction method and application of a spontaneous obesity model of a systemic GPX3 knock-gene mouse. The construction method comprises the following steps: preparing a precisely targeted GPX3 gene, knocking out a gene editing tool mixture of a specific segment (SEQ ID NO.1) of the GPX3 gene, transferring the gene editing tool mixture into a fertilized egg, and mating a mouse until a stably inherited GPX3 gene knockout homozygous mouse is obtained. The GPX3 is knocked out through the CRISPR / Cas9 technology, the spontaneous obese mouse model which cannot be achieved in the prior art is successfully obtained, the model can simulate obesity-related multi-organ lesions and diabetes mellitus progress, and a reliable tool is provided for obesity mechanism research and drug research and development.

The invention discloses application of recombinant CLCF1 protein in treatment of metabolic diseases, and belongs to the field of biological medicine. According to the invention, obese mice accompanied with abnormal glycolipid metabolism are taken as research objects, and the function of the CLCF1 recombinant protein in mice with metabolic syndromes is researched by a method of intraperitoneal injection of the CLCF1 recombinant protein. The result shows that compared with a control mouse, the 1 mg / kg CLCF1 recombinant protein has the advantage that the weight, hyperlipemia, hyperglycemia and liver fatty degeneration of the obese mouse are obviously reduced when being used for treating the obese mouse. Aiming at the functions of the CLCF1, the CLCF1 can be used for preparing medicines for treating obesity-related diseases.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The invention belongs to the technical field of medicines, and discloses a composition with the effects of resisting obesity, reducing blood fat and building muscles as well as a preparation method and application of the composition. The composition provided by the invention comprises the following components: bupleurum smithii, tobacco aureocauda, physochlaina, ganoderma lucidum sporocarp, ganoderma lucidum spore powder and ganoderma lucidum spore powder wall shells. The ganoderma lucidum spore powder wall shell is innovatively used as one of the components of the composition, and full utilization of traditional Chinese medicine waste is achieved. The composition has a synergistic effect, can significantly reduce the weight, blood fat (triglyceride and total cholesterol) level and fat (epididymal fat and groin fat) weight of obese mice, and increases the total weight of muscles (flatfish muscle, gastrocnemius muscle, tibia anterior muscle, biceps brachii muscle and triceps brachii muscle).

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating obesity phenotype and glycolipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating obesity phenotype and glycolipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No.1. The invention firstly verifies the influence of Sdccag3 overexpression on the weight, fat size and fat distribution of the obese mouse, and finds that the overexpression Sdccag3 can significantly improve the weight, fat size and fat distribution of the obese mouse. Then, it is found that specific overexpression of Sdccag3 in adipose tissue in a mouse can significantly inhibit increase of blood fat level, reduce fat volume of an obese mouse, reduce serum triglyceride, cholesterol and low-density lipoprotein cholesterol levels of the obese mouse, improve glucose intolerance and improve insulin sensitivity, and the Sdccag3 can be used for treating obesity. The fat phenotype and glycolipid metabolism are effectively regulated and controlled, the weight losing effect is achieved, and the composition can be used for preparing lipid-lowering and weight-losing medicines.